Efficacy News and Research

RSS

Stereotaxis to be featured prominently in 31st HRS

Stereotaxis' safety and efficacy in the treatment of patients with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, and congenital heart defects will be featured prominently in the scientific program of the 31st Annual Heart Rhythm Scientific Sessions in Denver, Colorado. Eight podium presentations and eight posters will underscore the broad clinical leadership that Stereotaxis has achieved in the treatment of patients with complex cardiac arrhythmias.

13 May 2010

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.

13 May 2010

Advances in vaccine delivery and efficacy discussed at National Immunization Conference

Advances in vaccine delivery and efficacy were discussed at the 44th National Immunization Conference sponsored by the Centers for Disease Control and Prevention. A research study by each of the four directors from the Center for Vaccine Awareness and Research at Texas Children's Hospital was presented.

13 May 2010

Amarin reports cash balance of $44 million for first-quarter 2010

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported selected financial results for the fiscal quarter ended March 31, 2010 and provided a progress update of the Company's ANCHOR and MARINE trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.

13 May 2010

Sex can affect frequency and severity of adverse effects of vaccination

Biological differences between the sexes could be a significant predictor of responses to vaccines, according to researchers at the Johns Hopkins Bloomberg School of Public Health. They examined published data from numerous adult and child vaccine trials and found that sex is a fundamental, but often overlooked predictor of vaccine response that could help predict the efficacy of combating infectious disease.

13 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

13 May 2010

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific Corporation today announced it has received CE Mark approval for its TAXUS Element Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent technology. This approval includes a specific indication for the treatment of diabetic patients.

13 May 2010

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, has received CE Mark approval for its TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System, Boston Scientific's third-generation drug-eluting stent (DES) technology.

13 May 2010

Avexa halts HIV drug trials

Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.

12 May 2010

RBC Life Sciences first-quarter net sales increase 16% to $7.0M

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported company-wide net sales of $7.0 million for the first quarter ended March 31, 2010, compared to net sales of $6.0 million for the same period during 2009, an increase of 16%.

12 May 2010

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

GTC Biotherapeutics, Inc. today reported its financial results for the first fiscal quarter ended April 4, 2010. The total net loss for the first quarter was $7.7 million, or $0.26 per share, compared to $10.4 million, or $0.99 per share, for the first quarter of 2009.

12 May 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.

12 May 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.

12 May 2010

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

“We have very good experience with Aldara in Europe and we look forward to provide AK patients with a new product with improved tolerability that builds on the efficacy of imiquimod”

12 May 2010

Researchers discover molecular mechanism behind smoking cessation effect

The tobacco addiction epidemic is a major public health problem worldwide. Professor Zhao Baolu and his group from the State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Chinese Academy of Sciences set out to tackle this problem. After 20 years of innovative research, they have developed a novel tea filter to treat cigarette addiction and have discovered the molecular mechanism behind the smoking cessation effect.

12 May 2010

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced the launch of the OptiDDITM Suite, a novel assay panel that assesses the most clinically significant transporter-related drug-drug interactions (DDIs), as identified by the International Transporter Consortium (ITC) in its report "Membrane Transporters in Drug Development" (Nature Reviews-Drug Discovery, March 2010).

12 May 2010

Oncos Therapeutics completes € 4 million investment from HealthCap

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

12 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

Efficacy News and Research

Stereotaxis to be featured prominently in 31st HRS

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Advances in vaccine delivery and efficacy discussed at National Immunization Conference

Amarin reports cash balance of $44 million for first-quarter 2010

Sex can affect frequency and severity of adverse effects of vaccination

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Avexa halts HIV drug trials

RBC Life Sciences first-quarter net sales increase 16% to $7.0M

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

Researchers discover molecular mechanism behind smoking cessation effect

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Oncos Therapeutics completes € 4 million investment from HealthCap

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News